Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company, is seeking an experienced Director, Translational Pharmacokinetics – DMPK to provide pharmacokinetic modeling leadership for early-stage development programs across its portfolio. Centessa is a clinical-stage company developing orexin receptor 2 (OX2R) agonists for narcolepsy and potentially other sleep-wake disorders. Its lead investigational candidate, cleminorexton, is being developed for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. The Director will develop and validate physiologically based pharmacokinetic (PBPK) models to simulate drug absorption, distribution, metabolism, and excretion (ADME), as well as drug-drug interactions (DDI). The role also develops and evolves pharmacokinetic and pharmacodynamic (PKPD) models and first-in-human (FIH) dose projections. It involves analyzing nonclinical and clinical data, preparing simulation reports, and collaborating with cross-functional teams to support drug development. The successful candidate will integrate data from in vitro and pharmacokinetic studies to simulate ADME and DDI, optimize dosing regimens, and support regulatory submissions. The role also contributes to candidate selection, program transition from research into development, scientific recommendations to senior leadership, and mentoring junior scientists.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director
Education Level
Ph.D. or professional degree